Loading stock data…
GMED
$77.95-7.12 (-8.37%)
Market ClosedLast close May 8
Globus Medical, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Globus Medical, Inc. in the Healthcare sector is trading at $77.95. The stock is currently 23% below its 52-week high of $101.40, remaining 0.1% above its 200-day moving average. Technical signals show oversold RSI of 18 and bearish MACD signal, explaining why GMED maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 18) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$77.95
Potential Downside
19.3%
Whystock Fair Value$62.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$110.08+41.2%
Range$90.00 – $123.00
Fundamentals
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle scre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.23
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.80%
Volume
Today's trading volume
5.75M
Recent News
GMED Stock Rises on Q1 Earnings & Revenue Beat, '26 EPS View Raised
Globus Medical beats Q1 EPS estimates by 22% as revenues rise 27% to $759.9M; margins widen and 2026 EPS outlook up, lifting shares 5.8%.
Globus Medical (GMED) Tops Q1 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +22.07% and +4.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, Globus Medical (GMED) Q1 Earnings: A Look at Key Metrics
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q1 2026 Earnings Transcript
Joining today's call from Globus Medical, Inc. will be Keith W. Pfeil, President and CEO, and Kyle Kline, Chief Financial Officer. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.
Globus Medical’s (NYSE:GMED) Q1 CY2026: Beats On Revenue
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 27% year on year to $759.9 million. The company expects the full year’s revenue to be around $3.2 billion, close to analysts’ estimates. Its non-GAAP profit of $1.12 per share was 21.7% above analysts’ consensus estimates.